NGL Fine Chem Ltd
NGL Fine Chem Q3 FY25: Revenue ₹89.10 Cr, PAT ₹1.28 Cr
Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹89Cr
- +1.1% YoY
- Net profit
- ₹1Cr
- −90% YoY
- Margin
- 6%
- −10 pp YoY
Guidance rank: #34 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on NGL Fine Chem Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Q3FY25 EBITDA: ₹5.10 Crores, down 63.25% YoY - Q3FY25 EBITDA Margin: 5.72%, down 1005 bps YoY - Q3FY25 Profit After Tax (PAT): ₹1.28 Crores, down 87.28% YoY
From NGL Fine Chem Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8).
- Total income for Q3FY25: ₹88.97 crores, down 2.91% Y-o-Y (Page 8).
- EBITDA for Q3FY25 was ₹5.10 crores, a sharp Y-o-Y decline of 63.25% (Page 8).
- Quarterly operational metrics show segmental revenue mix for Q3FY25 as: Animal API 93%, Human API 2%, Intermediates 2%, Formulations 3% (Page 7).
2 more points from NGL Fine Chem Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Brownfield Expansion:
- Ongoing initiative to increase capacities to meet growing demand.
- Greenfield Expansion at Tarapur:
- Completed expansion in subsidiary Macrotech.
- Additional capacities of intermediates with commercial production started.
- 50% capacity expansion to meet demand for new products in pipeline.
- Estimated capex of ₹160 Crores.
- Funded through debt and internal accrual.
- Civil construction ongoing; ₹80.59 Crores invested till Q3FY25.
- Phase 1 of CAPEX project slated for completion in current quarter (Q4FY25).
2 more points from NGL Fine Chem Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
NGL Fine Chem Ltd — Quarterly revenue & net profit
NGL Fine Chem Ltd Q3 FY25 results — key figures
| ₹ Cr | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 89 | 88 | +1.1% | 93 | -4.3% |
| Operating profit (EBITDA) | 5 | 14 | -64.3% | 12 | -58.3% |
| Operating margin | 6% | 16% | -10 pp | 12% | -6 pp |
| Profit before tax | 1 | 14 | -92.9% | 13 | -92.3% |
| Net profit (PAT) | 1 | 10 | -90% | 10 | -90% |
| EPS (₹) | 2.07 | 16.24 | -87.3% | 15.88 | -87% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharmaceuticals (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
NGL Fine Chem Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were NGL Fine Chem Ltd Q3 FY25 results?
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Q3FY25 EBITDA: ₹5.10 Crores, down 63.25% YoY - Q3FY25 EBITDA Margin: 5.72%, down 1005 bps YoY - Q3FY25 Profit After Tax (PAT): ₹1.28 Crores, down 87.28% YoY
What is NGL Fine Chem Ltd share price analysis?
NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem Ltd planning capital expenditure?
Brownfield Expansion: - Ongoing initiative to increase capacities to meet growing demand.
Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.